Abiopharma

🔍 Kumar Neil (Director)

Company: BridgeBio Pharma, Inc. (BBIO)

Report Date: 2026-08-18

Detailed Transactions and Holdings:

• Sold 1,900 shares of Common Stock at $81.1494 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 276,407.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 17,279 shares of Common Stock at $82.2104 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 259,128.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 14,602 shares of Common Stock at $82.9922 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 244,526.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 1,199 shares of Common Stock at $83.7732 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 243,327.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 8,100 shares of Common Stock at $83.8588 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 507,586.00 | transaction_form_type: 4 | Footnotes: F1, F6, F7
• Sold 1,800 shares of Common Stock at $84.6867 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 505,786.00 | transaction_form_type: 4 | Footnotes: F1, F8, F7
• Sold 100 shares of Common Stock at $85.65 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 505,686.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: H | nature_of_ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | shares_owned_after: 3,568,447.00 | Footnotes: F7
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: H | nature_of_ownership: By NK 2026 GRAT | shares_owned_after: 750,000.00 | Footnotes: F9

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
• F2: Represents the weighted average sale price of the shares sold from $80.54 to $81.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
• F3: Represents the weighted average sale price of the shares sold from $81.62 to $82.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
• F4: Represents the weighted average sale price of the shares sold from $82.62 to $83.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
• F5: Represents the weighted average sale price of the shares sold from $83.65 to $83.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
• F6: Represents the weighted average sale price of the shares sold from $83.34 to $84.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
• F7: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
• F8: Represents the weighted average sale price of the shares sold from $84.35 to $85.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
• F9: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.